Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Income before tax

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Dec 31, 2025-2,145+3.08%
Dec 31, 2024-2,081+84.74%
Dec 31, 2023-1,126-11.93%
Dec 31, 2022-1,279+144.52%
Dec 31, 2021-523-51.44%
Dec 31, 2020-1,077-212.53%
Dec 31, 2019957-182.57%
Dec 31, 2018-1,159+62.93%
Dec 31, 2017-711+61.46%
Dec 31, 2016-441-189.52%
Dec 31, 2015492-181.07%
Dec 31, 2014-607+119.60%
Dec 31, 2013-276-37.54%
Dec 31, 2012-443+30.11%
Dec 31, 2011-340

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat